LXR 623
Alternative Names: LXR-623Latest Information Update: 21 Dec 2016
At a glance
- Originator Karo Bio
- Class Cardiovascular therapies; Indazoles
- Mechanism of Action Liver X receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 20 Sep 2007 Discontinued - Phase-I for Atherosclerosis in Japan (PO)
- 20 Sep 2007 Discontinued - Phase-I for Atherosclerosis in USA (PO)